The Soviet and Russian pharmacology community pursued cognitive-enhancement research with a distinctive combination of theoretical starting points and institutional structure. Theoretically, the community took seriously the idea that endogenous peptides could be used as templates for cognitive-therapeutic drug design — ACTH fragments (Semax), tuftsin analogues (Selank), pineal-gland peptide extracts (Epitalon, Pinealon), and cortical peptide preparations (Cortexin, Cerebrolysin) all come from the same conceptual root: modify a known endogenous signalling molecule to retain its cognitive-relevant effects while removing unwanted broader physiology.

Institutionally, the Russian Academy of Sciences provided the long-term research settings and the pharmacology-institute framework that turned academic discovery into clinical evaluation. Semax, Selank, Noopept, Cerebrolysin, and Cortexin all received Russian clinical approval in the 1990s and 2000s and entered routine Russian clinical practice — an accumulation of clinical evidence that Western cognitive-peptide research has not matched.

The result is a body of Russian-language peer-reviewed literature — much of it in Zhurnal Nevrologii i Psikhiatrii, Elibrary.ru-indexed pharmacology and clinical journals — that provides deeper mechanistic and clinical characterisation of these compounds than exists in the English-language literature. Access to that literature, and appreciation of the Russian clinical-approval evidence, is central to reading the compounds accurately.

Three things stand out. First: clinical trial depth. The Russian community ran phased clinical evaluation on Semax, Selank, Noopept, Cerebrolysin, Cortexin, and Epitalon in populations (post-stroke rehabilitation, mild cognitive impairment, generalised anxiety, elderly cohorts, paediatric neurology) that Western researchers rarely reach with peptide interventions.

Second: long-term real-world safety data. Semax and Selank have been in Russian clinical use since the 1990s and Cerebrolysin since the 1970s. The real-world pharmacovigilance databases attached to these compounds are qualitatively different from anything in the English-language research-peptide literature.

Third: combined-protocol research. The most-replicated multi-peptide protocol in the world — Semax + Selank for stress-under-cognitive-load research — comes out of the Russian tradition. The stack-research literature is more developed on the Russian side.

What the Russian literature does not cover as well as one might like: placebo-controlled trials in Western cognitive-population samples, mechanistic work at the receptor-pharmacology level of resolution common in Western neuroscience, and chronic-dosing safety beyond the standard cycled-course convention.